Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Saved in:
Bibliographic Details
Published inThe lancet oncology Vol. 23; no. 7; pp. 833 - 835
Main Authors Oosting, Sjoukje F, van der Veldt, Astrid A M, Fehrmann, Rudolf S N, GeurtsvanKessel, Corine H, van Binnendijk, Rob S, Dingemans, Anne-Marie C, Smit, Egbert F, Hiltermann, T Jeroen N, den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T, Bhattacharya, Arkajyoti, de Wilt, Faye, Boerma, Annemarie, van Zijl, Lisanne, Rimmelzwaan, Guus F, Kvistborg, Pia, van Els, Cecile A C M, Rots, Nynke Y, van Baarle, Debbie, Haanen, John B A G, de Vries, Elisabeth G E
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.07.2022
Elsevier Limited
Subjects
Antibodies
Cancer
Chemotherapy
Comment
Immune response (humoral)
Immunogenicity
Immunoglobulin G
Immunotherapy
Infections
Lymphocytes
Lymphocytes T
mRNA
R&D
Research & development
Severe acute respiratory syndrome coronavirus 2
Solid tumors
Tumors
Vaccination
Netherlands
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(22)00203-0